Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 539524 | NSE: LALPATHLAB

Dr Lal Pathlabs Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 9, 2025, 8:00 pm

Market Cap 20,842 Cr.
Current Price 2,493
High / Low 3,654/1,943
Stock P/E50.0
Book Value 239
Dividend Yield0.96 %
ROCE25.2 %
ROE20.4 %
Face Value 10.0
PEG Ratio6.80

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Dr Lal Pathlabs Ltd

Competitors of Dr Lal Pathlabs Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
NG Industries Ltd 57.0 Cr. 170 206/1364.70 1242.06 %6.50 %5.63 % 10.0
Global Longlife Hospital and Research Ltd 25.5 Cr. 24.2 46.4/22.1 25.90.00 %2.51 %4.72 % 10.0
Gian Lifecare Ltd 18.1 Cr. 17.5 29.0/12.14.43 19.20.00 %29.2 %24.6 % 10.0
Fortis Malar Hospitals Ltd 118 Cr. 62.7 108/44.0153 15.967.8 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 26.7 Cr. 4.95 9.50/4.320.70 2.670.00 %15.4 %24.1 % 10.0
Industry Average22,314.27 Cr670.2353.4489.393.10%12.34%12.42%9.12

All Competitor Stocks of Dr Lal Pathlabs Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 497486503534489491541601539545602660597
Expenses 388364385390376375395424398401432458443
Operating Profit 109121118144113116146178141145170202154
OPM % 22%25%23%27%23%24%27%30%26%27%28%31%26%
Other Income 121289101414181818212225
Interest 912811998877665
Depreciation 31383639383835363637353536
Profit before tax 8284811037683118152116120150183138
Tax % 29%26%28%30%30%32%29%27%29%28%28%29%29%
Net Profit 58625872545784111828610813198
EPS in Rs 6.887.356.928.606.336.809.9013.099.7410.1212.7515.4611.57

Last Updated: March 3, 2025, 4:42 pm

Below is a detailed analysis of the quarterly data for Dr Lal Pathlabs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹597.00 Cr.. The value appears to be declining and may need further review. It has decreased from 660.00 Cr. (Sep 2024) to ₹597.00 Cr., marking a decrease of 63.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹443.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 458.00 Cr. (Sep 2024) to ₹443.00 Cr., marking a decrease of 15.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Sep 2024) to ₹154.00 Cr., marking a decrease of 48.00 Cr..
  • For OPM %, as of Dec 2024, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 31.00% (Sep 2024) to 26.00%, marking a decrease of 5.00%.
  • For Other Income, as of Dec 2024, the value is ₹25.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Sep 2024) to ₹25.00 Cr., marking an increase of ₹3.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹5.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 6.00 Cr. (Sep 2024) to ₹5.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹36.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Sep 2024) to ₹36.00 Cr., marking an increase of ₹1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹138.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Sep 2024) to ₹138.00 Cr., marking a decrease of 45.00 Cr..
  • For Tax %, as of Dec 2024, the value is 29.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 29.00%.
  • For Net Profit, as of Dec 2024, the value is ₹98.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Sep 2024) to ₹98.00 Cr., marking a decrease of 33.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 11.57. The value appears to be declining and may need further review. It has decreased from ₹15.46 (Sep 2024) to 11.57, marking a decrease of ₹3.89.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:26 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 4525586607919121,0571,2031,3301,5812,0872,0172,2272,404
Expenses 3544195045826757939109871,1451,5261,5271,6171,733
Operating Profit 98139156210238264294344436561490609671
OPM % 22%25%24%26%26%25%24%26%28%27%24%27%28%
Other Income 381220273146555152426986
Interest 0000111151630382924
Depreciation 202728282833387377108150144142
Profit before tax 80119140201237261301310394475344505591
Tax % 31%33%31%34%34%34%33%27%25%26%30%28%
Net Profit 558096133156172200228296350241362422
EPS in Rs 1,643.22148.2717.5115.9918.6120.4923.9027.1134.9941.3728.6542.8549.90
Dividend Payout % 9%7%9%15%16%22%25%44%57%29%21%42%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)45.45%20.00%38.54%17.29%10.26%16.28%14.00%29.82%18.24%-31.14%50.21%
Change in YoY Net Profit Growth (%)0.00%-25.45%18.54%-21.25%-7.04%6.02%-2.28%15.82%-11.58%-49.39%81.35%

Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:15%
5 Years:13%
3 Years:12%
TTM:11%
Compounded Profit Growth
10 Years:16%
5 Years:12%
3 Years:7%
TTM:26%
Stock Price CAGR
10 Years:%
5 Years:10%
3 Years:-1%
1 Year:21%
Return on Equity
10 Years:23%
5 Years:21%
3 Years:20%
Last Year:20%

Last Updated: Unknown

Balance Sheet

Last Updated: January 13, 2025, 3:49 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 3545583838383838383838384
Reserves 1571512604255127058629491,1621,4181,5831,7661,918
Borrowings 2282700000150533420247198
Other Liabilities 10611913411895128145341265309297357397
Total Liabilities 2693524756256909161,0911,3741,6612,3432,3832,4542,598
Fixed Assets 1271401501661522082094134471,3691,3051,2281,189
CWIP 101418103111015561
Investments 55938641061451851645965150114289
Other Assets 872032863914145546947861,1448939231,1071,119
Total Assets 2693524756256909161,0911,3741,6612,3432,3832,4542,598

Below is a detailed analysis of the balance sheet data for Dr Lal Pathlabs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹84.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹83.00 Cr. (Mar 2024) to ₹84.00 Cr., marking an increase of 1.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,918.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,766.00 Cr. (Mar 2024) to ₹1,918.00 Cr., marking an increase of 152.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹198.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹247.00 Cr. (Mar 2024) to ₹198.00 Cr., marking a decrease of 49.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹397.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹357.00 Cr. (Mar 2024) to ₹397.00 Cr., marking an increase of 40.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹2,598.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹2,454.00 Cr. (Mar 2024) to ₹2,598.00 Cr., marking an increase of 144.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹1,189.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹1,228.00 Cr. (Mar 2024) to ₹1,189.00 Cr., marking a decrease of 39.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹1.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹6.00 Cr. (Mar 2024) to ₹1.00 Cr., marking a decrease of 5.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹289.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹114.00 Cr. (Mar 2024) to ₹289.00 Cr., marking an increase of 175.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹1,119.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,107.00 Cr. (Mar 2024) to ₹1,119.00 Cr., marking an increase of 12.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹2,598.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,454.00 Cr. (Mar 2024) to ₹2,598.00 Cr., marking an increase of 144.00 Cr..

Notably, the Reserves (₹1,918.00 Cr.) exceed the Borrowings (198.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +8898122159171197219284398447456535
Cash from Investing Activity +-64-89-113-163-137-172-100-26-212-449-287-24
Cash from Financing Activity +-15-10-10-3213-55-190-139136-283-414
Net Cash Flow9-28-5237646748134-11497

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow96.00111.00129.00210.00238.00264.00294.00344.00286.0028.0070.00362.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days161617171714161415151313
Inventory Days37313344407039382830
Days Payable908997106111144132107127151
Cash Conversion Cycle1616-35-42-47-47-55-60-78-54-87-108
Working Capital Days-39-26-92719170-19-17-14-19-23
ROCE %58%60%48%47%43%38%35%32%33%29%18%25%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters55.23%55.05%55.04%55.04%55.03%55.01%54.61%54.60%54.60%54.60%53.92%53.91%
FIIs23.44%22.37%23.26%25.80%24.89%23.27%24.35%25.36%26.15%25.43%26.82%26.82%
DIIs6.83%6.52%6.27%6.20%6.56%8.34%8.85%9.27%9.40%12.42%12.60%12.88%
Government0.00%0.00%0.00%0.00%0.00%0.29%0.29%0.29%0.29%0.29%0.29%0.29%
Public13.80%15.46%14.84%12.38%13.01%12.65%11.48%10.12%9.24%6.95%6.02%5.82%
Others0.70%0.60%0.58%0.56%0.51%0.44%0.41%0.37%0.32%0.30%0.33%0.28%
No. of Shareholders1,71,8461,84,5081,71,6021,79,6361,80,1631,74,4441,60,6791,49,9011,46,7411,31,1891,16,6061,16,236

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Flexi Cap Fund1,517,7231.68401.871,517,7232025-03-100%
HDFC Flexi Cap Fund - Regular Plan1,192,2100.58315.681,517,7232025-03-10-21.45%
SBI Large & Midcap Fund650,0000.73172.111,517,7232025-03-10-57.17%
HDFC ELSS Tax Saver Fund539,8000.97142.931,517,7232025-03-10-64.43%
UTI Mid Cap Fund529,7301.31140.261,517,7232025-03-10-65.1%
Nippon India Pharma Fund425,0001.57112.531,517,7232025-03-10-72%
PGIM India Midcap Opportunities Fund388,8081.02102.951,517,7232025-03-10-74.38%
HDFC Hybrid Equity Fund - Regular Plan242,9570.2864.331,517,7232025-03-10-83.99%
Edelweiss Arbitrage Fund193,8000.4451.321,517,7232025-03-10-87.23%
UTI Small Cap Fund158,4651.1141.961,517,7232025-03-10-89.56%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 43.0528.8241.7035.3327.42
Diluted EPS (Rs.) 42.9828.7441.7035.2527.37
Cash EPS (Rs.) 60.6046.9355.0044.8336.04
Book Value[Excl.RevalReserv]/Share (Rs.) 225.85203.86185.20153.10126.48
Book Value[Incl.RevalReserv]/Share (Rs.) 225.85203.86185.20153.10126.48
Revenue From Operations / Share (Rs.) 266.73241.93250.45189.72159.63
PBDIT / Share (Rs.) 81.2763.7673.5858.5147.83
PBIT / Share (Rs.) 64.0645.7460.6149.2439.09
PBT / Share (Rs.) 60.5541.2456.9947.3237.25
Net Profit / Share (Rs.) 43.4028.9242.0335.5727.31
NP After MI And SOA / Share (Rs.) 42.8528.6541.3734.9927.10
PBDIT Margin (%) 30.4626.3529.3730.8329.96
PBIT Margin (%) 24.0118.9024.2025.9524.48
PBT Margin (%) 22.7017.0422.7524.9423.33
Net Profit Margin (%) 16.2711.9516.7818.7417.10
NP After MI And SOA Margin (%) 16.0611.8416.5118.4416.97
Return on Networth / Equity (%) 19.3414.3322.8623.4221.86
Return on Capital Employeed (%) 26.8619.9027.2529.5828.40
Return On Assets (%) 14.5610.0114.6517.5516.43
Long Term Debt / Equity (X) 0.000.050.110.000.00
Total Debt / Equity (X) 0.040.140.220.000.00
Asset Turnover Ratio (%) 0.910.850.961.011.06
Current Ratio (X) 2.422.071.754.183.93
Quick Ratio (X) 2.342.001.654.023.68
Dividend Payout Ratio (NP) (%) 55.7641.6233.5533.9856.52
Dividend Payout Ratio (CP) (%) 39.7825.5525.5426.8742.75
Earning Retention Ratio (%) 44.2458.3866.4566.0243.48
Cash Earning Retention Ratio (%) 60.2274.4574.4673.1357.25
Interest Coverage Ratio (X) 23.1114.1620.3230.4726.05
Interest Coverage Ratio (Post Tax) (X) 13.347.4212.6119.5315.88
Enterprise Value (Cr.) 18177.2514843.3421493.2321670.2911132.07
EV / Net Operating Revenue (X) 8.167.3610.3013.708.37
EV / EBITDA (X) 26.7927.9235.0544.4427.93
MarketCap / Net Operating Revenue (X) 8.487.5610.4114.278.78
Retention Ratios (%) 44.2358.3766.4466.0143.47
Price / BV (X) 10.219.1514.4118.1211.31
Price / Net Operating Revenue (X) 8.487.5610.4114.278.78
EarningsYield 0.010.010.010.010.01

After reviewing the key financial ratios for Dr Lal Pathlabs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 43.05. This value is within the healthy range. It has increased from 28.82 (Mar 23) to 43.05, marking an increase of 14.23.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 42.98. This value is within the healthy range. It has increased from 28.74 (Mar 23) to 42.98, marking an increase of 14.24.
  • For Cash EPS (Rs.), as of Mar 24, the value is 60.60. This value is within the healthy range. It has increased from 46.93 (Mar 23) to 60.60, marking an increase of 13.67.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 225.85. It has increased from 203.86 (Mar 23) to 225.85, marking an increase of 21.99.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 225.85. It has increased from 203.86 (Mar 23) to 225.85, marking an increase of 21.99.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 266.73. It has increased from 241.93 (Mar 23) to 266.73, marking an increase of 24.80.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 81.27. This value is within the healthy range. It has increased from 63.76 (Mar 23) to 81.27, marking an increase of 17.51.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 64.06. This value is within the healthy range. It has increased from 45.74 (Mar 23) to 64.06, marking an increase of 18.32.
  • For PBT / Share (Rs.), as of Mar 24, the value is 60.55. This value is within the healthy range. It has increased from 41.24 (Mar 23) to 60.55, marking an increase of 19.31.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 43.40. This value is within the healthy range. It has increased from 28.92 (Mar 23) to 43.40, marking an increase of 14.48.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 42.85. This value is within the healthy range. It has increased from 28.65 (Mar 23) to 42.85, marking an increase of 14.20.
  • For PBDIT Margin (%), as of Mar 24, the value is 30.46. This value is within the healthy range. It has increased from 26.35 (Mar 23) to 30.46, marking an increase of 4.11.
  • For PBIT Margin (%), as of Mar 24, the value is 24.01. This value exceeds the healthy maximum of 20. It has increased from 18.90 (Mar 23) to 24.01, marking an increase of 5.11.
  • For PBT Margin (%), as of Mar 24, the value is 22.70. This value is within the healthy range. It has increased from 17.04 (Mar 23) to 22.70, marking an increase of 5.66.
  • For Net Profit Margin (%), as of Mar 24, the value is 16.27. This value exceeds the healthy maximum of 10. It has increased from 11.95 (Mar 23) to 16.27, marking an increase of 4.32.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 16.06. This value is within the healthy range. It has increased from 11.84 (Mar 23) to 16.06, marking an increase of 4.22.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 19.34. This value is within the healthy range. It has increased from 14.33 (Mar 23) to 19.34, marking an increase of 5.01.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 26.86. This value is within the healthy range. It has increased from 19.90 (Mar 23) to 26.86, marking an increase of 6.96.
  • For Return On Assets (%), as of Mar 24, the value is 14.56. This value is within the healthy range. It has increased from 10.01 (Mar 23) to 14.56, marking an increase of 4.55.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 23) to 0.00, marking a decrease of 0.05.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. It has decreased from 0.14 (Mar 23) to 0.04, marking a decrease of 0.10.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.91. It has increased from 0.85 (Mar 23) to 0.91, marking an increase of 0.06.
  • For Current Ratio (X), as of Mar 24, the value is 2.42. This value is within the healthy range. It has increased from 2.07 (Mar 23) to 2.42, marking an increase of 0.35.
  • For Quick Ratio (X), as of Mar 24, the value is 2.34. This value exceeds the healthy maximum of 2. It has increased from 2.00 (Mar 23) to 2.34, marking an increase of 0.34.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 55.76. This value exceeds the healthy maximum of 50. It has increased from 41.62 (Mar 23) to 55.76, marking an increase of 14.14.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 39.78. This value is within the healthy range. It has increased from 25.55 (Mar 23) to 39.78, marking an increase of 14.23.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 44.24. This value is within the healthy range. It has decreased from 58.38 (Mar 23) to 44.24, marking a decrease of 14.14.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 60.22. This value is within the healthy range. It has decreased from 74.45 (Mar 23) to 60.22, marking a decrease of 14.23.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 23.11. This value is within the healthy range. It has increased from 14.16 (Mar 23) to 23.11, marking an increase of 8.95.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 13.34. This value is within the healthy range. It has increased from 7.42 (Mar 23) to 13.34, marking an increase of 5.92.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 18,177.25. It has increased from 14,843.34 (Mar 23) to 18,177.25, marking an increase of 3,333.91.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 8.16. This value exceeds the healthy maximum of 3. It has increased from 7.36 (Mar 23) to 8.16, marking an increase of 0.80.
  • For EV / EBITDA (X), as of Mar 24, the value is 26.79. This value exceeds the healthy maximum of 15. It has decreased from 27.92 (Mar 23) to 26.79, marking a decrease of 1.13.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 8.48. This value exceeds the healthy maximum of 3. It has increased from 7.56 (Mar 23) to 8.48, marking an increase of 0.92.
  • For Retention Ratios (%), as of Mar 24, the value is 44.23. This value is within the healthy range. It has decreased from 58.37 (Mar 23) to 44.23, marking a decrease of 14.14.
  • For Price / BV (X), as of Mar 24, the value is 10.21. This value exceeds the healthy maximum of 3. It has increased from 9.15 (Mar 23) to 10.21, marking an increase of 1.06.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 8.48. This value exceeds the healthy maximum of 3. It has increased from 7.56 (Mar 23) to 8.48, marking an increase of 0.92.
  • For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dr Lal Pathlabs Ltd as of March 12, 2025 is: ₹1,968.96

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Dr Lal Pathlabs Ltd is Overvalued by 21.02% compared to the current share price 2,493.00

Intrinsic Value of Dr Lal Pathlabs Ltd as of March 12, 2025 is: 2,113.82

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Dr Lal Pathlabs Ltd is Overvalued by 15.21% compared to the current share price 2,493.00

Last 5 Year EPS CAGR: 7.36%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 38.83%, which is a positive sign.
  2. The stock has a low average Working Capital Days of -8.58, which is a positive sign.
  3. The stock has a low average Cash Conversion Cycle of -48.42, which is a positive sign.
  4. The company has higher reserves (912.92 cr) compared to borrowings (123.46 cr), indicating strong financial stability.
  5. The company has shown consistent growth in sales (260.38 cr) and profit (304.46 cr) over the years.

    Stock Analysis

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lal Pathlabs Ltd:
      1. Net Profit Margin: 16.27%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: 26.86% (Industry Average ROCE: 12.34%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 19.34% (Industry Average ROE: 12.42%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): 13.34
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 2.34
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. Stock P/E: 50 (Industry average Stock P/E: 53.44)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. Total Debt / Equity: 0.04
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating:

    About the Company - Qualitative Analysis

    Dr. Lal Pathlabs Ltd. is a Public Limited Listed company incorporated on 14/02/1995 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1995PLC065388 and registration number is 065388. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 1966.76 Cr. and Equity Capital is Rs. 83.48 Cr. for the Year ended 31/03/2024.
    INDUSTRYADDRESSCONTACT
    Hospitals & Medical ServicesBlock E, New Delhi Delhi 110085cs@lalpathlabs.com
    https://www.lalpathlabs.com
    Management
    NamePosition Held
    Brig.(Hony) Dr. Arvind LalExecutive Chairman
    Dr. Om Prakash ManchandaManaging Director
    Dr. Vandana LalWhole Time Director
    Mr. Rahul SharmaNon Executive Director
    Dr. Archana Lal ErdmannNon Executive Director
    Mr. Gurinder Singh KalraIndependent Director
    Mr. Rajit MehtaIndependent Director
    Mrs. Somya SatsangiIndependent Director
    Mr. Rohit BhasinIndependent Director
    Mr. Arun DuggalIndependent Director

    FAQ

    What is the latest intrinsic value of Dr Lal Pathlabs Ltd?

    The latest intrinsic value of Dr Lal Pathlabs Ltd as on 11 March 2025 is ₹1968.96, which is 21.02% lower than the current market price of 2,493.00, indicating the stock is overvalued by 21.02%. The intrinsic value of Dr Lal Pathlabs Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹20,842 Cr. and recorded a high/low of ₹3,654/1,943 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,918 Cr and total liabilities of ₹2,598 Cr.

    What is the Market Cap of Dr Lal Pathlabs Ltd?

    The Market Cap of Dr Lal Pathlabs Ltd is 20,842 Cr..

    What is the current Stock Price of Dr Lal Pathlabs Ltd as on 11 March 2025?

    The current stock price of Dr Lal Pathlabs Ltd as on 11 March 2025 is ₹2,493.

    What is the High / Low of Dr Lal Pathlabs Ltd stocks in FY 2024-2025?

    In FY 2024-2025, the High / Low of Dr Lal Pathlabs Ltd stocks is ₹3,654/1,943.

    What is the Stock P/E of Dr Lal Pathlabs Ltd?

    The Stock P/E of Dr Lal Pathlabs Ltd is 50.0.

    What is the Book Value of Dr Lal Pathlabs Ltd?

    The Book Value of Dr Lal Pathlabs Ltd is 239.

    What is the Dividend Yield of Dr Lal Pathlabs Ltd?

    The Dividend Yield of Dr Lal Pathlabs Ltd is 0.96 %.

    What is the ROCE of Dr Lal Pathlabs Ltd?

    The ROCE of Dr Lal Pathlabs Ltd is 25.2 %.

    What is the ROE of Dr Lal Pathlabs Ltd?

    The ROE of Dr Lal Pathlabs Ltd is 20.4 %.

    What is the Face Value of Dr Lal Pathlabs Ltd?

    The Face Value of Dr Lal Pathlabs Ltd is 10.0.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Dr Lal Pathlabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE